Saturday, August 24, 2024 12:07:03 PM
jman4956,
The next Direct trial should/will be stopped very early for efficacy and followed for long term benefit. The efficacy will be so obvious that the Germans would stop it before anyone else if the trial has patients from that country on SOC. That’s the only reason I would like to see at least some patients compared to SOC because then they could be crossed over to treatment and be given the same chance as anyone else for a cure as long as they did not have totally compromised immune systems by then. This means enrolling SOC patients with at least as much life expectancy or a little more than those later enrolled in the Direct Phase 1 trial after inclusion criteria was raised up a little. Once Direct proves itself, true valuation will have no problem being found by the general investment community nor will the greatly decreased value of many big pharma products be ignored. At that point or just before someone will begin to short big pharma and go long NWBO. Free money for those so inclined. Keeping NWBO independent and wholly owned by current longs until then is the key to maximizing returns for these same. This is why I expect to see some major fireworks in 2025-2026. By that time many big pharma oncology products will be toast and they know it now already. This is why they are cutting back in early project research. Anyone who sells NWBO out of need or desire to help others in some way from now until then is understandable. Anyone who sells for any other reason except perhaps traders on hoped for swings until that point will miss out big time for no good purpose in my opinion. Best wishes.
The next Direct trial should/will be stopped very early for efficacy and followed for long term benefit. The efficacy will be so obvious that the Germans would stop it before anyone else if the trial has patients from that country on SOC. That’s the only reason I would like to see at least some patients compared to SOC because then they could be crossed over to treatment and be given the same chance as anyone else for a cure as long as they did not have totally compromised immune systems by then. This means enrolling SOC patients with at least as much life expectancy or a little more than those later enrolled in the Direct Phase 1 trial after inclusion criteria was raised up a little. Once Direct proves itself, true valuation will have no problem being found by the general investment community nor will the greatly decreased value of many big pharma products be ignored. At that point or just before someone will begin to short big pharma and go long NWBO. Free money for those so inclined. Keeping NWBO independent and wholly owned by current longs until then is the key to maximizing returns for these same. This is why I expect to see some major fireworks in 2025-2026. By that time many big pharma oncology products will be toast and they know it now already. This is why they are cutting back in early project research. Anyone who sells NWBO out of need or desire to help others in some way from now until then is understandable. Anyone who sells for any other reason except perhaps traders on hoped for swings until that point will miss out big time for no good purpose in my opinion. Best wishes.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
